Literature DB >> 6094609

Propagation and assay of hepatitis A virus in vitro.

G Siegl, J deChastonay, G Kronauer.   

Abstract

Ten strains of hepatitis A virus (HAV) originating from far distant geographical locations were adapted to growth in PLC/PRF/5 (human hepatoma derived and/or MRC-5 (human embryonic lung) cells. In the course of primary adaptation some of these strains exhibited a predilection for distinct cultural conditions such as type of host cell and temperature of incubation. With progressive passage, variant viruses with quite different requirements could be selected; yet, it proved impossible to isolate a virus which replicated equally well in both types of cells and at both 32 and 37 degrees C without at least one preceding passage under the new conditions. Analysis of the virus/cell relationship of well adapted HAV strains revealed that the replication cycle of HAV extends over about 24 h. Moreover, replication evidently passes from a state of active production of infectious virus to a phase during which hepatitis A antigen (HAAg) is synthesized and terminates in the state of persistent infection with markedly reduced synthetic activity. In all three phases replication of HAV is non-cytolytic and the vast majority of both infectious virus and of HAAg remains cell associated. The observations concerning the growth characteristics of HAV were used to develop two rapid in vitro assay systems for HAV infectivity (fluorescent focus assay and in situ RIA). Finally, the conditions for large scale production of infectious HAV and of HAAg in a cell factory system were analysed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6094609     DOI: 10.1016/0166-0934(84)90083-1

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  14 in total

Review 1.  Diagnosis of hepatitis a virus infection: a molecular approach.

Authors:  Omana V Nainan; Guoliang Xia; Gilberto Vaughan; Harold S Margolis
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Stable growth of wild-type hepatitis A virus in cell culture.

Authors:  Krishnamurthy Konduru; Gerardo G Kaplan
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  The effect of lipophilic amines on the growth of hepatitis A virus in Frp/3 cells.

Authors:  F Superti; L Seganti; N Orsi; M Divizia; R Gabrieli; A Panà
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

4.  Adsorption, purification, and growth characteristics of hepatitis A virus strain HAS-15 propagated in fetal rhesus monkey kidney cells.

Authors:  C M Wheeler; H A Fields; C A Schable; W J Meinke; J E Maynard
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

5.  Detection of a genome-linked protein (VPg) of hepatitis A virus and its comparison with other picornaviral VPgs.

Authors:  M Weitz; B M Baroudy; W L Maloy; J R Ticehurst; R H Purcell
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

6.  Morphological changes in HAV-infected Frp/3 cells and immunolocalization of HAAg.

Authors:  A Tinari; F M Ruggeri; M Divizia; A Panà; G Donelli
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

7.  Identification of active-site residues in protease 3C of hepatitis A virus by site-directed mutagenesis.

Authors:  R Gosert; G Dollenmaier; M Weitz
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  Morphogenesis of hepatitis A virus: isolation and characterization of subviral particles.

Authors:  D A Anderson; B C Ross
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

9.  Proteins specifically binding to the 3' untranslated region of hepatitis A virus RNA in persistently infected cells.

Authors:  J P Nüesch; M Weitz; G Siegl
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

10.  Hepatitis A virus-encoded miRNAs attenuate the accumulation of viral genomic RNAs in infected cells.

Authors:  Jiandong Shi; Jing Sun; Meini Wu; Ningzhu Hu; Yunzhang Hu
Journal:  Virus Genes       Date:  2016-03-02       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.